Motoko Yamaguchi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5791116/publications.pdf

Version: 2024-02-01

81	4,609	156536	111975
papers	citations	32 h-index	67 g-index

86	86	86	3306
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Longâ€term outcomes and central nervous system relapse in extranodal natural killer/Tâ€cell lymphoma. Hematological Oncology, 2022, 40, 667-677.	0.8	0
2	Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study â€" JCOG0108A. Journal of Clinical and Experimental Hematopathology: JCEH, 2021, 61, 35-41.	0.3	0
3	DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica, 2020, 105, 2308-2315.	1.7	21
4	Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data. International Journal of Hematology, 2020, 112, 807-816.	0.7	8
5	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 593-602.	5.1	55
6	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood, 2020, 136, 2548-2556.	0.6	17
7	Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. International Journal of Hematology, 2020, 111, 686-691.	0.7	11
8	JSH practical guidelines for hematological malignancies, 2018: 7. Peripheral T-cell lymphoma (PTCL). International Journal of Hematology, 2019, 109, 137-140.	0.7	7
9	Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin. Annals of Hematology, 2019, 98, 1647-1655.	0.8	19
10	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK/T-cell lymphoma, nasal type (ENKL). International Journal of Hematology, 2019, 109, 371-376.	0.7	7
11	Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy. Blood, 2019, 134, 1624-1624.	0.6	0
12	Early disease progression in patients with localized natural killer/Tâ€cell lymphoma treated with concurrent chemoradiotherapy. Cancer Science, 2018, 109, 2056-2062.	1.7	18
13	Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood, 2018, 131, 2528-2540.	0.6	155
14	Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematology,the, 2018, 5, e520-e531.	2.2	14
15	Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. Best Practice and Research in Clinical Haematology, 2018, 31, 315-321.	0.7	32
16	MYD88, CD79B, and CARD11 gene mutations in CD5â€positive diffuse large Bâ€cell lymphoma. Cancer, 2017, 123, 1166-1173.	2.0	20
17	Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. Journal of Clinical Oncology, 2017, 35, 32-39.	0.8	122
18	Current treatment approaches for NK/T-cell lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 98-108.	0.3	32

#	Article	IF	Citations
19	Topics on the molecular pathogenesis and therapeutic approaches for T/NK-cell lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 85-86.	0.3	0
20	Expressions of <scp>SH</scp>3<scp>BP</scp>5, <scp>LMO</scp>3, and <scp>SNAP</scp>25 in diffuse large Bâ€cell lymphoma cells and their association with clinical features. Cancer Medicine, 2016, 5, 1802-1809.	1.3	10
21	Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. International Journal of Hematology, 2015, 102, 188-194.	0.7	25
22	Prognostic biomarkers in patients with localized natural killer/Tâ€cell lymphoma treated with concurrent chemoradiotherapy. Cancer Science, 2014, 105, 1435-1441.	1.7	17
23	NK-Cell Neoplasms. , 2013, , 87-103.		0
24	Reply to A. Chan et al. Journal of Clinical Oncology, 2012, 30, 1016-1017.	0.8	4
25	Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type. Clinical Cancer Research, 2012, 18, 4183-4190.	3.2	86
26	Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan Clinical Oncology Group Study JCOG0211. Journal of Clinical Oncology, 2012, 30, 4044-4046.	0.8	123
27	Current and future management of NK/T-cell lymphoma based on clinical trials. International Journal of Hematology, 2012, 96, 562-571.	0.7	36
28	Prospective measurement of Epstein-Barr virusâ€“DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood, 2011, 118, 6018-6022.	0.6	175
29	Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. European Journal of Haematology, 2011, 86, 117-123.	1.1	7
30	Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study. Journal of Clinical Oncology, 2011, 29, 4410-4416.	0.8	532
31	Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial. Journal of Clinical Oncology, 2011, 29, 3990-3998.	0.8	59
32	Central nervous system involvement in intravascular large Bâ€cell lymphoma: A retrospective analysis of 109 patients. Cancer Science, 2010, 101, 1480-1486.	1.7	107
33	Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leukemia and Lymphoma, 2010, 51, 813-821.	0.6	30
34	Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II Study. Blood, 2010, 116, 2873-2873.	0.6	2
35	Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211. Journal of Clinical Oncology, 2009, 27, 5594-5600.	0.8	315
36	Gene expression profiling of peripheral T-cell lymphoma including Î³Î´ T-cell lymphoma. Blood, 2009, 113, 1071-1074.	0.6	64

#	Article	IF	Citations
37	Phase I study of dexamethasone, methotrexate, ifosfamide, <scp>l</scp>â€asparaginase, and etoposide (SMILE) chemotherapy for advancedâ€stage, relapsed or refractory extranodal natural killer (NK)/Tâ€cell lymphoma and leukemia. Cancer Science, 2008, 99, 1016-1020.	1.7	193
38	Gene expression profiling of diffuse large Bâ€cell lymphoma supervised by CD21 expression. British Journal of Haematology, 2008, 142, 562-570.	1.2	12
39	Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan. Journal of Clinical Oncology, 2008, 26, 3189-3195.	0.8	250
40	De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica, 2008, 93, 1195-1202.	1.7	113
41	Evaluation of Central Nervous System Recurrence of Intravascular Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy. Blood, 2008, 112, 4933-4933.	0.6	0
42	Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood, 2007, 109, 478-485.	0.6	399
43	Clinicopathologic Significance of Loss of CD19 Expression in Diffuse Large B-Cell Lymphoma. International Journal of Hematology, 2007, 85, 41-48.	0.7	9
44	Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy. Thrombosis Research, 2006, 117, 671-679.	0.8	10
45	De novo CD5-positive Diffuse Large B-cell Lymphoma of the Temporal Bone Presenting with an External Auditory Canal Tumor. Internal Medicine, 2006, 45, 733-737.	0.3	19
46	Contrast-enhanced ultrasound examination of lymph nodes in different types of lymphoma. Cancer Detection and Prevention, 2006, 30, 188-191.	2.1	29
47	Extra Nodal NK/T-Cell Lymphoma Nasal Type that Responded to DeVIC Combination Chemotherapy. Journal of Dermatology, 2005, 32, 204-209.	0.6	7
48	NK-cell neoplasms in Japan. Hematology, 2005, 10, 237-245.	0.7	95
49	CD5 + Diffuse Large B-Cell Lymphoma Consists of Germline Cases and Hypermutated Cases in the Immunoglobulin Heavy Chain Gene Variable Region. International Journal of Hematology, 2005, 81, 58-61.	0.7	4
50	Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. Genes Chromosomes and Cancer, 2005, 42, 149-157.	1.5	32
51	Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thrombosis and Haemostasis, 2005, 93, 153-159.	1.8	34
52	Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. International Journal of Oncology, 2005, 27, 1241.	1.4	4
53	CD19-Negative Diffuse Large B-Cell Lymphoma Shows High Serum LDH Level and Poor Prognosis.. Blood, 2005, 106, 1924-1924.	0.6	24
54	Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI.. Blood, 2005, 106, 2685-2685.	0.6	5

#	Article	IF	Citations
55	Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell Lymphoma. Cancer Research, 2004, 64, 5948-5955.	0.4	66
56	Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas. International Journal of Oncology, 2004, 24, 497.	1.4	4
57	CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. British Journal of Haematology, 2004, 125, 180-186.	1.2	13
58	Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene, 2004, 23, 9148-9154.	2.6	35
59	Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosomes and Cancer, 2004, 39, 77-81.	1.5	43
60	Quantization and similarity measure selection for discrimination of lymphoma subtypes under k-nearest neighbor classification. , 2004, 5328, 6.		3
61	Hepatosplenic Î³Î´ T-cell Lymphoma: Difficulty in Diagnosis. Internal Medicine, 2004, 43, 83-84.	0.3	1
62	High Incidence of Asian Variant Intravascular Large B-Cell Lymphoma (IVL) among IVL in Japan: Clinicopathologic Study of 95 Patients.. Blood, 2004, 104, 1365-1365.	0.6	3
63	TREATMENT FOR NASAL NK/T-CELL LYMPHOMA. Japanese Journal of Head and Neck Cancer, 2004, 30, 358-362.	0.0	0
64	Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies. Cancer Science, 2003, 94, 87-91.	1.7	35
65	Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer Research, 2003, 63, 60-6.	0.4	46
66	De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood, 2002, 99, 815-821.	0.6	273
67	Development of Diffuse Large Cell Lymphoma from Follicular Lymphoma with Multiple Immunoglobulin Heavy Chain Gene Rearrangement Occurring in a Patient with Wiskott-Aldrich Syndrome. International Journal of Hematology, 2002, 76, 196-198.	0.7	5
68	Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori. Gastrointestinal Endoscopy, 2001, 54, 92-96.	0.5	24
69	Endosonographic Images of Low-grade Lymphoma of Mucosa-associated Lymphoid Tissue After Radiotherapy. Journal of Clinical Gastroenterology, 2001, 33, 237-240.	1.1	7
70	Additional t(11;17)(q23;q21) in a patient with Philadelphia-positive mixed lineage antigen-expressing leukemia. Cancer Genetics and Cytogenetics, 2001, 126, 8-12.	1.0	19
71	Morphological spectrum of cyclin D1-positive mantle cell lymphoma: Study of 168 cases. Pathology International, 2001, 51, 747-761.	0.6	44
72	Treatment outcome of nasal NK-cell lymphoma: A report of 12 consecutively-diagnosed cases and a review of the literature.. Journal of Clinical and Experimental Hematopathology: JCEH, 2001, 41, 93-99.	0.3	46

#	Article	IF	Citations
73	Successful treatment of lymphoid follicular proctitis with sulfasalazine suppositories. American Journal of Gastroenterology, 2000, 95, 2403-2404.	0.2	7
74	Gastric mucosa-associated lymphoid tissue lymphoma with a focal high-grade component diagnosed by EUS and endoscopic mucosal resection for histologic evaluation. Gastrointestinal Endoscopy, 2000, 51, 752-755.	0.5	15
75	De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. British Journal of Haematology, 1999, 105, 1133-1139.	1.2	68
76	De Novo CD5+ Diffuse Large B-Cell Lymphomas Express VH Genes With Somatic Mutation. Blood, 1998, 91, 1145-1151.	0.6	92
77	Î³/Í´ T-Cell Lymphoma of the Thyroid Gland. New England Journal of Medicine, 1997, 336, 1391-1392.	13.9	43
78	Expression of interleukin-5 receptors on acute myeloid leukaemia cells: association with immunophenotype and karyotype. British Journal of Haematology, 1995, 91, 169-172.	1.2	7
79	Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer, 1995, 76, 2351-2356.	2.0	269
80	SlOO-positive Histiocytes in T-Cell-dependent Area in Human Lymph Nodes Express P-Glycoprotein. Japanese Journal of Cancer Research, 1994, 85, 946-951.	1.7	1
81	PRAD1 gene overâ€expression in mantleâ€cell lymphoma but not in other lowâ€grade Bâ€cell lymphomas, including extranodal lymphoma. British Journal of Haematology, 1994, 86, 786-791.	1.2	65